Preservative-free bimatoprost 0.03% in patients with primary open-angle glaucoma or ocular hypertension in clinical practice.
BACKGROUND
Intraocular pressure (IOP)-lowering medications for primary open-angle glaucoma and ocular hypertension commonly contain preservatives that can cause ocular surface damage in many patients. The purpose of this study was to evaluate the efficacy and tolerability of, and compliance to, preservative-free (PF) bimatoprost 0.03% in patients with primary open-angle glaucoma or ocular hypertension (IOP ≥18 mmHg) in a clinical practice setting.


METHODS
This open-label study observed patients who were switched to PF bimatoprost 0.03% for medical reasons. IOP was measured at baseline and ~12 weeks later at the final visit, and the change in IOP was calculated. Tolerability and continuation of therapy were assessed at two follow-up visits.


RESULTS
A total of 1,830 patients were included in the study, and complete IOP data were available for 1,543 patients. Mean IOP was reduced by 23% from 21.64 mmHg to 16.59 mmHg (P<0.0001). In subgroup analyses, the mean IOP was significantly reduced compared with baseline, regardless of prior therapy, including those previously treated with PF monotherapy. A total of 85.7% of physicians reported the IOP-lowering efficacy of PF bimatoprost 0.03% to be as expected or better than expected. Adverse events (AEs) were experienced by 5.7% of patients, and there were no serious AEs reported. The most common AEs were eye irritation (1.7%) and hyperemia (1.4%). Physician-reported treatment compliance was reported as better than (48.7%) or equal to (43.6%) prior treatment in most patients. Most patients (82%) were expected to continue PF bimatoprost 0.03% after the end of the study.


CONCLUSIONS
This observational study showed that, in clinical practice, switching to PF bimatoprost 0.03% was associated with a significant IOP reduction from baseline. There was a low AE rate. PF bimatoprost 0.03% may, therefore, be an effective treatment option for patients who are intolerant of preservatives or have an inadequate response to prior IOP-lowering treatments.
Department of Ophthalmology, University Hospital Carl Gustav Carus, Dresden.
Lutz E
LE
Pillunat
Ophthalmology Practice, Kiel.
Peter
P
Eschstruth
Eye Center Kraichgau, Wiesloch.
Stefan
S
Häsemeyer
Department of Ophthalmology, University of Münster, Münster.
Ulrich
U
Thelen
Ophthalmology Practice, Leipzig, Germany.
Christian
C
Foja
Allergan Holdings Ltd., Marlow, UK.
Richard
R
Leaback
Ophthalmology Practice, Polch, Germany.
Stefan
S
Pfennigsdorf
benzalkonium chloride free; bimatoprost 0.03%; intraocular pressure; preservative free; prostaglandin
Br J Ophthalmol. 2011 Jun;95(6):869-75
21429894
Ocul Surf. 2007 Apr;5(2):75-92
17508116
Invest Ophthalmol Vis Sci. 2007 Mar;48(3):1149-55
17325158
Cornea. 2012 Sep;31(9):994-9
22710490
Ophthalmology. 2008 Feb;115(2):233-8
17655930
J Clin Epidemiol. 2009 Dec;62(12):1279-83
19716679
Invest Ophthalmol Vis Sci. 2006 Oct;47(10):4309-15
17003420
Eur J Ophthalmol. 2007 May-Jun;17(3):341-9
17534814
Clin Ophthalmol. 2011;5:623-31
21629567
Br J Ophthalmol. 2002 Apr;86(4):418-23
11914211
Eur J Ophthalmol. 2013 Jul-Aug;23(4):518-25
23483513
Ophthalmology. 2009 Oct;116(10):1846-53
19592110
Br J Ophthalmol. 2013 Aug;97(8):989-93
23743437
Ocul Surf. 2007 Apr;5(2):179-93
17508121
J Glaucoma. 2008 Dec;17(8):667-73
19092464
Prog Retin Eye Res. 2010 Jul;29(4):312-34
20302969
Ophthalmology. 2005 Jul;112(7):1177-85
15921747